Abstract:Background Fibrosis is defined as an excessive accumulation of extracellular matrix (ECM) components. Many organs are subjected to fibrosis including the lung, liver, heart, skin, kidney, and muscle. Muscle fibrosis occurs in response to trauma, aging, or dystrophies and impairs muscle function. Fibrosis represents a hurdle for the treatment of human muscular dystrophies. While data on the mechanisms of fibrosis have mostly been investigated in mice, dystrophic mouse models often do not recapitulate fibrosis as observed in human patients. Consequently, the cellular and molecular mechanisms that lead to fibrosis in human muscle still need to be identified. Methods Combining mass cytometry, transcriptome profiling, in vitro co-culture experiments, and in vivo transplantation in immunodeficient mice, we investigated the role and nature of nonmyogenic cells (fibroadipogenic progenitors, FAPs) from human fibrotic muscles of healthy individuals (FibM CT ) and individuals with oculopharyngeal muscular dystrophy (OPMD; FibM OP ), as compared with nonmyogenic cells from human nonfibrotic muscle (M CT ). Results We found that the proliferation rate of FAPs from fibrotic muscle is 3–4 times higher than those of FAPs from nonfibrotic muscle (population doubling per day: M CT 0.2 ± 0.1, FibM CT 0.7 ± 0.1, and FibM OP 0.8 ± 0.3). When cocultured with muscle cells, FAPs from fibrotic muscle impair the fusion index unlike M CT FAPs (myoblasts alone 57.3 ± 11.1%, coculture with M CT 43.1 ± 8.9%, with FibM CT 31.7 ± 8.2%, and with FibM OP 36.06 ± 10.29%). We also observed an increased proliferation of FAPs from fibrotic muscles in these co-cultures in differentiation conditions (FibM CT +17.4%, P < 0.01 and FibM OP +15.1%, P < 0.01). This effect is likely linked to the increased activation of the canonical TGFβ-SMAD pathway in FAPs from fibrotic muscles evidenced by pSMAD3 immunostaining ( P < 0.05). In addition to the profibrogenic TGFβ pathway, we identified endothelin as a new actor implicated in the altered cross-talk between muscle cells and fibrotic FAPs, confirmed by an improvement of the fusion index in the presence of bosentan, an endothelin receptor antagonist (from 33.8 ± 10.9% to 52.9 ± 10.1%, P < 0.05). Conclusions Our data demonstrate the key role of FAPs and their cross-talk with muscle cells through a paracrine signalling pathway in fibrosis of human skeletal muscle and identify endothelin as a new druggable target to counteract human muscle fibrosis.

Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors

miR-27b-3p reduces muscle fibrosis during chronic skeletal muscle injury by targeting TGF-βR1/Smad pathway

Inhibition of PDGF, TGF-β, and Abl Signaling and Reduction of Liver Fibrosis by the Small Molecule Bcr-Abl Tyrosine Kinase Antagonist Nilotinib

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Tuning Macrophage Phenotype to Mitigate Skeletal Muscle Fibrosis

Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat

Nintedanib Exerts Anti-Pulmonary Fibrosis Activity Via Inhibiting TANK-binding Kinase 1 (TBK1) Phosphorylation

The Adipokine Adiponectin Has Potent Anti-Fibrotic Effects Mediated Via Adenosine Monophosphate-Activated Protein Kinase: Novel Target for Fibrosis Therapy

NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling

Anlotinib Attenuated Bleomycin-Induced Pulmonary Fibrosis Via the TGF-β1 Signalling Pathway.

Adiponectin Alleviates Intestinal Fibrosis by Enhancing AMP-Activated Protein Kinase Phosphorylation

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis

Tumor Necrosis Factor-Alpha Modulates Expression of Genes Involved in Cytokines and Chemokine Pathways in Proliferative Myoblast Cells

A negative feedback loop between fibroadipogenic progenitors and muscle fibres involving endothelin promotes human muscle fibrosis

Deletion of delta-like 1 homologue accelerates fibroblast–myofibroblast differentiation and induces myocardial fibrosis

Omentin-1 Induces Mechanically Activated Fibroblasts Lipogenic Differentiation Through Pkm2/yap/pparγ Pathway to Promote Lung Fibrosis Resolution

Fibroblast Nrf2 inhibits profibrotic transcription with Ddx54 and mitigates pathological fibrosis in the mouse heart and kidney

Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity

Proteasomal Inhibition after Injury Prevents Fibrosis by Modulating TGF-β1 Signalling

Axitinib attenuates the progression of liver fibrosis by restoring mitochondrial function